- Home
- BIIB vs ARCC Comparison
BIIB vs ARCC Comparison
Compare BIIB & ARCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- ARCC
- Stock Information
- Founded
- BIIB 1978
- ARCC 2004
- Country
- BIIB United States
- ARCC United States
- Employees
- BIIB N/A
- ARCC N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- ARCC Finance/Investors Services
- Sector
- BIIB Health Care
- ARCC Finance
- Exchange
- BIIB Nasdaq
- ARCC Nasdaq
- Market Cap
- BIIB 18.7B
- ARCC 15.8B
- IPO Year
- BIIB 1991
- ARCC 2004
- Fundamental
- Price
- BIIB $149.17
- ARCC $19.09
- Analyst Decision
- BIIB Buy
- ARCC Buy
- Analyst Count
- BIIB 26
- ARCC 9
- Target Price
- BIIB $182.82
- ARCC $23.00
- AVG Volume (30 Days)
- BIIB 1.8M
- ARCC 6.6M
- Earning Date
- BIIB 10-30-2025
- ARCC 10-28-2025
- Dividend Yield
- BIIB N/A
- ARCC 10.05%
- EPS Growth
- BIIB 31.67
- ARCC N/A
- EPS
- BIIB 10.45
- ARCC 2.03
- Revenue
- BIIB $9,997,000,000.00
- ARCC $3,011,000,000.00
- Revenue This Year
- BIIB $2.00
- ARCC $3.21
- Revenue Next Year
- BIIB N/A
- ARCC $5.02
- P/E Ratio
- BIIB $14.31
- ARCC $9.39
- Revenue Growth
- BIIB 3.36
- ARCC 6.85
- 52 Week Low
- BIIB $110.04
- ARCC $18.26
- 52 Week High
- BIIB $194.13
- ARCC $23.84
- Technical
- Relative Strength Index (RSI)
- BIIB 56.57
- ARCC 19.56
- Support Level
- BIIB $135.39
- ARCC $20.03
- Resistance Level
- BIIB $160.20
- ARCC $20.43
- Average True Range (ATR)
- BIIB 4.43
- ARCC 0.40
- MACD
- BIIB 0.56
- ARCC -0.10
- Stochastic Oscillator
- BIIB 54.23
- ARCC 3.67
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About ARCC Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and subordinated debt, generally in a first lien position) and second lien senior secured loans. In addition to senior secured loans, the company also invests in subordinated loans and preferred equity, it also makes common equity investments.